First Time Loading...
C

Cyclopharm Ltd
ASX:CYC

Watchlist Manager
Cyclopharm Ltd
ASX:CYC
Watchlist
Price: 1.67 AUD -1.76% Market Closed
Updated: May 15, 2024

Gross Margin
Cyclopharm Ltd

63.1%
Current
70%
Average
47.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
63.1%
=
Gross Profit
17.5m
/
Revenue
27.8m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
AU
Cyclopharm Ltd
ASX:CYC
157.1m AUD
63%
US
Abbott Laboratories
NYSE:ABT
180.9B USD
55%
US
Intuitive Surgical Inc
NASDAQ:ISRG
136.3B USD
66%
US
Stryker Corp
NYSE:SYK
123.5B USD
64%
IE
Medtronic PLC
NYSE:MDT
112.1B USD
66%
US
Boston Scientific Corp
NYSE:BSX
108B USD
69%
US
Becton Dickinson and Co
NYSE:BDX
67.9B USD
41%
DE
Siemens Healthineers AG
XETRA:SHL
59.1B EUR
36%
CN
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
378.2B CNY
65%
US
Edwards Lifesciences Corp
NYSE:EW
52B USD
77%
US
Dexcom Inc
NASDAQ:DXCM
49.9B USD
63%
C
Cyclopharm Ltd
ASX:CYC
Country AU
Market Cap 157.1m AUD
Gross Margin
63%
Abbott Laboratories
NYSE:ABT
Country US
Market Cap 180.9B USD
Gross Margin
55%
Intuitive Surgical Inc
NASDAQ:ISRG
Country US
Market Cap 136.3B USD
Gross Margin
66%
Stryker Corp
NYSE:SYK
Country US
Market Cap 123.5B USD
Gross Margin
64%
Medtronic PLC
NYSE:MDT
Country IE
Market Cap 112.1B USD
Gross Margin
66%
Boston Scientific Corp
NYSE:BSX
Country US
Market Cap 108B USD
Gross Margin
69%
Becton Dickinson and Co
NYSE:BDX
Country US
Market Cap 67.9B USD
Gross Margin
41%
Siemens Healthineers AG
XETRA:SHL
Country DE
Market Cap 59.1B EUR
Gross Margin
36%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Country CN
Market Cap 378.2B CNY
Gross Margin
65%
Edwards Lifesciences Corp
NYSE:EW
Country US
Market Cap 52B USD
Gross Margin
77%
Dexcom Inc
NASDAQ:DXCM
Country US
Market Cap 49.9B USD
Gross Margin
63%

Profitability Report

View the profitability report to see the full profitability analysis for Cyclopharm Ltd.

Full Profitability Report

See Also

Summary
CYC intrinsic value, competitors valuation, and company profile.
DCF Valuation
CYC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CYC stock valuation using valuation multiples.
Wall Street Estimates
CYC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CYC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
63.1%
=
Gross Profit
17.5m
/
Revenue
27.8m
What is the Gross Margin of Cyclopharm Ltd?

Based on Cyclopharm Ltd's most recent financial statements, the company has Gross Margin of 63.1%.

ALPHA SPREAD
Join more than 137,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.